Hanmi Pharmaceutical signed an exclusive licensing agreement with Genetech, a subsidiary of the Roche Group, for the next generation of new obesity drug candidates, with a maximum transaction scale of 3.5 trillion won. The drug not only has weight loss effects, but also has excellent muscle protection effects, and the market expects it to grow into a core drug candidate for the next generation of obesity treatment tracks.

Hanmi Pharmaceutical signed an exclusive licensing agreement with Genetech, a subsidiary of the Roche Group, for the next generation of new obesity drug candidates, with a maximum transaction scale of 3.5 trillion won. The drug not only has weight loss effects, but also has excellent muscle protection effects, and the market expects it to grow into a core drug candidate for the next generation of obesity treatment tracks.